Global Biobank Meta-analysis Initiative: Powering genetic discovery across human disease

Summary

The Global Biobank Meta-analysis Initiative represents a collaborative effort integrating genetic and clinical data from 2.2 million individuals across 23 biobanks on four continents to conduct large-scale genome-wide association studies. By demonstrating that GWASs can be robustly meta-analysed despite heterogeneity in case definitions and recruitment strategies, the initiative advances genetic discovery for multiple human diseases whilst addressing the historical underrepresentation of non-European ancestry individuals in biobank research. The approach enables improved disease gene nomination, drug candidate identification, and risk prediction through integration of genomic, gene expression, and protein expression data.

Regional applicability

This collaborative international study includes biobank data from multiple continents and likely includes biobanks from the United Kingdom or Europe, making findings applicable to UK clinical genetics research and disease risk prediction. The emphasis on improving diversity in genetic studies has implications for UK biobank initiatives such as UK Biobank, which could benefit from similar meta-analytic approaches and efforts to include underrepresented ancestry groups.

Key measures

GWAS summary statistics from harmonised genotypes and phenotypes; disease and trait associations across 14 exemplar conditions; power for disease gene nomination and risk prediction; ancestry diversity across biobanks

Outcomes reported

The study meta-analysed genome-wide association study (GWAS) summary statistics from 23 biobanks across 4 continents representing 2.2 million individuals with genetic data linked to electronic health records for 14 exemplar diseases and endpoints. The analysis demonstrated that GWASs from diverse biobanks can be integrated and used to improve genetic discovery, risk prediction, and identification of disease genes and drug candidates.

Topic tags